文献速递毛发、甲与色素性疾病

硫唑嘌呤、甲氨蝶呤与环孢素作为慢性斑秃保类固醇药物的续用率:138例回顾性研究

Utility of azathioprine, methotrexate and cyclosporine as steroid-sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2020-09-01

该回顾性研究纳入2002至2019年138例接受硫唑嘌呤、甲氨蝶呤或环孢素治疗的慢性斑秃患者,主要结局为6和12个月续用率。12个月总续用率为66.7%,硫唑嘌呤75.3%、甲氨蝶呤50%、环孢素60.5%;多数续用者需联用小剂量泼尼松龙。

要点

  • 慢性斑秃中硫唑嘌呤是最常被使用的保类固醇药物。
  • 12个月续用率:硫唑嘌呤75.3%、甲氨蝶呤50%、环孢素60.5%。
  • 多数续用者需联用小剂量泼尼松龙维持疗效。

核心结论

  • 本诊所慢性斑秃患者最常使用的保类固醇药物为硫唑嘌呤。
  • 多数开始硫唑嘌呤、甲氨蝶呤或环孢素治疗的患者持续治疗至少12个月,且多需联用小剂量泼尼松龙。

研究设计与样本

  • 回顾性研究,通过电子病历检索2002至2019年852例斑秃患者,其中138例接受硫唑嘌呤、甲氨蝶呤或环孢素治疗。
  • 主要结局为保类固醇药物6和12个月续用率,并记录斑秃类型、治疗时长、停药原因及联用泼尼松龙情况。

主要发现

  • 138例接受保类固醇药物治疗的患者中,92例(66.7%)持续治疗至少12个月。
  • 12个月续用率:硫唑嘌呤75.3%(55/73)、甲氨蝶呤50%(11/22)、环孢素60.5%(26/43)。
  • 12个月时,硫唑嘌呤使用者中67.3%需联用泼尼松龙,平均日剂量5.6 mg;甲氨蝶呤使用者中63.6%需联用,平均日剂量5 mg;环孢素使用者中57.7%需联用,平均日剂量8.7 mg。
  • 15.9%的患者因不良事件停用保类固醇药物,17.4%因疗效不足停用。

关键数值与推荐

  • 12个月续用率:硫唑嘌呤75.3%(55/73)、甲氨蝶呤50%(11/22)、环孢素60.5%(26/43)。
  • 12个月时联用泼尼松龙比例及平均日剂量:硫唑嘌呤67.3%、5.6 mg;甲氨蝶呤63.6%、5 mg;环孢素57.7%、8.7 mg。
  • 停用保类固醇药物原因:不良事件15.9%,疗效不足17.4%。

临床怎么用

  • 在慢性斑秃中,硫唑嘌呤在本队列中续用率最高,可作为保类固醇治疗的选择之一。
  • 开始保类固醇药物治疗时,应预期多数患者需联用小剂量泼尼松龙以维持缓解或促进毛发再生。
  • 需监测不良事件和疗效,因部分患者会因不良事件或疗效不足停药。

局限性

  • 回顾性研究设计,可能存在选择偏倚和信息偏倚。
  • 单中心电子病历数据,样本量有限(138例接受保类固醇药物治疗)。
  • 无头对头临床试验比较不同保类固醇药物的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of chronic alopecia areata (CAA) is challenging. There is currently no therapy that produces consistent successful hair regrowth. Systemic therapies, including prednisolone and steroid-sparing agents (SSA), are often tried in patients with CAA. As there are no head-to-head clinical trials that compare efficacy of one SSA over another, retrospective studies of treatment in clinical practice may help guide clinical practice. OBJECTIVE: To investigate the utility of SSAs in the treatment of AA. METHODS: An electronic medical records search identified patients with AA and those prescribed azathioprine, cyclosporine or methotrexate between 2002 and 2019. Type of AA, treatment duration, reason for cessation, use of concurrent prednisolone, dose of prednisolone and duration of prednisolone use were recorded. The primary outcome was SSA continuation rate at 6 and 12 months. RESULTS: A total of 852 AA patients were identified, among whom 138 patients had been treated with azathioprine, methotrexate or cyclosporine. Of these 138 patients treated with a SSA, 92 (66.7%) continued treatment for at least 12 months: 75.3% (55/73) of azathioprine users, 50% (11/22) of methotrexate users and 60.5% (26/43) of cyclosporine users. At 12 months, 67.3% of azathioprine users required concurrent prednisolone at a mean dose of 5.6 mg daily, 63.6% of methotrexate users required prednisolone at a mean dose of 5 mg daily and 57.7% of cyclosporine users required prednisolone at a mean dose of 8.7 mg daily. The SSA was ceased due to an adverse event in 15.9% of patients and a lack of efficacy in 17.4%. CONCLUSION: The most well-utilized SSA for CAA patients at our clinic was azathioprine. This study highlights that most CAA patients who commence treatment with azathioprine, methotrexate or cyclosporine continue that treatment for at least 12 months and most require concurrent low-dose prednisolone to maintain remission or promote continued hair regrowth.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Lai VWY, Sinclair R. Utility of azathioprine, methotrexate and cyclosporine as steroid-sparing agents in chronic alopecia areata: a retrospective study of continuation rates in 138 patients. J Eur Acad Dermatol Venereol. 2020. PMID: 32779249. doi:10.1111/jdv.16858

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。